Silvana Martino

发表

Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Dongsheng Tu, Martine J Piccart, James N Ingle, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Peter A Kaufman, James N Ingle, Edith A Perez, 2002, Journal of the National Cancer Institute.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.

Ji-Yeob Choi, Robert B Livingston, Li Tang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Robert B Livingston, Dongsheng Tu, Jeffrey S Abrams, 2005, Journal of the National Cancer Institute.

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Molin Wang, George W. Sledge, Antonio C. Wolff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Peter A Kaufman, James N Ingle, Edith A Perez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Jong-Hyeon Jeong, Peter A Kaufman, Norman Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Jong-Hyeon Jeong, Norman Wolmark, Priya Rastogi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.